Literature DB >> 1171113

Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men.

J Weeke, A P Hansen, K Lundaek.   

Abstract

To elucidate the effect of somatostatin on basal, unstimulated TSH secretion 6 young healthy nonobese men were studied with blood samples every 15 min from 2300 h to 0500 h. Somatostatin 1 mg was indused over a 2-h period from 0100 h. One of the subjects was also studied with half hourly blood samples throughout a 26-h period without receiving somatostatin. In all cases the high night levels of serum thyrotropin (TSH) were significantly suppressed by somatostatin. The fall of TSH continued throughout the two hour infusion period. Immediately upon termination of the infusion serum TSH increased rapidly to preinfusion values. The 26-h control study showed the typical diurnal pattern of serum TSH with low values in the daytime and high values at night. The serum triiodothyronine (T3) and thyroxine (T4) levels were not changed by somatostatin infusion. From these results we suggest that endogenous somatostatin may be of physiological importance in the regulation of the TSH secretion.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1171113     DOI: 10.1210/jcem-41-1-168

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

2.  [Stimulation of growth hormone and prolactin secretion with TRH in acromegaly (author's transl)].

Authors:  K von Werder; R Fahlbusch; R Gay; C R Pickhardt; B Schultz
Journal:  Klin Wochenschr       Date:  1976-04-01

3.  Somatostatin inhibits release of thyrotropin releasing factor from organ cultures of rat hypothalamus.

Authors:  Y Hirooka; C S Hollander; S Suzuki; P Ferdinand; S I Juan
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

Review 4.  Risk factors of subclinical hypothyroidism and the potential contribution to miscarriage: A review.

Authors:  Shuhei So; Fumiko Tawara
Journal:  Reprod Med Biol       Date:  2020-03-18

5.  The influence of diabetes mellitus on thyrotropin response to thyrotropin-releasing hormone in untreated acromegalic patients.

Authors:  C Shigemasa; K Abe; S Taniguchi; Y Mitani; Y Ueta; T Adachi; K Urabe; T Tanaka; A Yoshida; T Hori
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

6.  Somatostatin inhibits rat hepatic T4-5'-deiodinase. The effect is independent of the associated hypoinsulinemia.

Authors:  L A Gavin; M Moeller
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

Review 7.  Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.

Authors:  Fatemeh G Amlashi; Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-21       Impact factor: 3.633

8.  Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.

Authors:  J M Kuhn; A Legrand; J M Ruiz; R Obach; J De Ronzan; F Thomas
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

9.  Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. Involvement of hypothalamic somatostatin.

Authors:  M Bermann; C A Jaffe; W Tsai; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

10.  Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism.

Authors:  Sneha Singh; Rishi K Somvanshi; Vandana Panda; Ujendra Kumar
Journal:  Endocrine       Date:  2020-04-25       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.